1-[1-[1-[(3-indolyl)carbonyl]piperidin-4-yl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one | 634616-85-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-[1-[1-[(3-indolyl)carbonyl]piperidin-4-yl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
• 英文别名: 3-[1-[1-(1H-indole-3-carbonyl)piperidin-4-yl]piperidin-4-yl]-1H-benzimidazol-2-one
• CAS: 634616-85-6
• 化学式: C₂₆H₂₉N₅O₂
• 分子量: 443.549
• InChiKey: IDYYWGZZXPUWJB-UHFFFAOYSA-N

物化性质

• 密度：
  1.328±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  33
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  71.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Ophthalmic compositions for treating ocular hypertension
  申请人：Ogidigben J Miller

  公开号：US20050176765A1

  公开（公告）日：2005-08-11

  This invention relates to selective m1 muscarinic agonist, their use or a formulation thereof in the treatment of glaucoma and/or other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans. In addition, the present invention relates to the use of the compounds in the treatment of dementia such as Alzheimer's disease and vascular dementia, depression, attention deficit disorder, sleep disorder, schizophrenia, pain, ischemia, atrophic gastritis, and atony of gastrointestinal tract.

  本发明涉及选择性m1肌动蛋白受体激动剂，它们的使用或制剂在治疗青光眼和/或与患者眼内压力升高有关的其他疾病方面。本发明还涉及使用这些化合物为哺乳动物，特别是人类的眼提供神经保护作用。此外，本发明还涉及使用这些化合物治疗痴呆症，如阿尔茨海默病和血管性痴呆，抑郁症，注意力缺陷障碍，睡眠障碍，精神分裂症，疼痛，缺血，萎缩性胃炎和胃肠道无力。
• EP1515722A4
  申请人：——

  公开号：EP1515722A4

  公开（公告）日：2006-06-21
• OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION
  申请人：Merck & Co., Inc.

  公开号：EP1515722A2

  公开（公告）日：2005-03-23
• US7279490B2
  申请人：——

  公开号：US7279490B2

  公开（公告）日：2007-10-09
• [EN] OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION<br/>[FR] COMPOSITIONS OPHTALMIQUES DESTINEES A TRAITER L'HYPERTENSION OCULAIRE
  申请人：MERCK & CO INC

  公开号：WO2003105781A2

  公开（公告）日：2003-12-24

  This invention relates to selective m1 muscarinic agonist, their use or a formulation thereof in the treatment of glaucoma and/or other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans. In addition, the present invention relates to the use of the compounds in the treatment of dementia such as Alzheimer's disease and vascular dementia, depression, attention deficit disorder, sleep disorder, schizophrenia, pain, ischemia, atrophic gastritis, and atony of gastrointestinal tract.